NASDAQ$UTMD
Utah Medical Products Inc · Q3 2022 earnings
Q3 2022 earnings · · Investor relations
Briefing
Achieved financial results that were better than anticipated despite challenges.
Utah Medical Products Inc. reported a 3% increase in revenues and a 1.8% increase in net income for Q3 2022 compared to Q3 2021, despite facing cost inflation, supply chain disruption, litigation expenses, and a stronger U.S. Dollar.
- Worldwide consolidated sales in all four major product categories were up in 3Q 2022 compared to 3Q 2021 despite a much stronger USD.
- Domestic U.S. sales in 3Q 2022 were $8,615 compared to $7,749 in 3Q 2021.
- The Company continued to realize substantial increases in manufacturing costs, highlighted by incoming freight on raw materials, which has doubled compared to 2021.
- At September 30, 2022, UTMD’s cash and investments increased $8,537 to $69,511 from $60,974 at the end of 2021.
Headline financials
Revenue & EPS history
Utah Medical · Revenue · Quarterly
$13M
Revenue by segment
Utah Medical · $7.98M total across 3 segments · Q1 2022
- Direct Sales$3.99M—50.0%
- OEM Sales$2.72M+42.6%34.0%
- Filshie Device Sales$1.28M—16.0%
Forward guidance
Management expects adjusted consolidated EBITDA of about $28 million for the full year 2022, consistent with previous projections.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2022
-0.1%
Avg return
Earnings day
-0.1%
Avg return
5 days after
+0.7%
Avg return
30 days after
43%
28 / 65 earnings
Positive
+6.8%
Q2 2019
Best reaction
-11.7%
Q4 2019
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +0.0% | -4.3% | -7.5% | |
| Q4 2025 | +1.2% | +1.9% | +9.5% | |
| Q3 2025 | -1.1% | -1.9% | -6.0% | |
| Q1 2025 | -0.2% | +0.9% | +4.3% | |
| Q4 2024 | -1.8% | -4.6% | -6.9% | |
| Q3 2024 | -0.3% | -0.2% | +1.4% | |
| Q2 2024 | -7.4% | -7.2% | -8.6% | |
| Q1 2024 | -1.8% | -1.4% | -0.2% | |
| Q4 2023 | -4.3% | -7.0% | -15.2% | |
| Q3 2023 | -3.1% | +0.0% | +4.2% | |
| Q2 2023 | +0.0% | +0.5% | -2.8% | |
| Q1 2023 | +0.8% | +0.8% | -0.6% | |
| Q4 2022 | +3.9% | +5.5% | +4.7% | |
| Q3 2022 | +3.5% | -1.3% | -0.1% | |
| Q2 2022 | +3.6% | +6.3% | +6.7% | |
| Q1 2022 | -1.2% | -3.1% | -4.6% | |
| Q4 2021 | -3.4% | -0.3% | -5.9% | |
| Q3 2021 | +4.7% | +1.7% | +30.7% | |
| Q2 2021 | +0.2% | +2.9% | -0.2% | |
| Q1 2021 | +0.6% | +0.8% | -0.4% | |
| Q4 2020 | +3.5% | +5.7% | +0.8% | |
| Q3 2020 | -3.4% | -1.7% | +6.3% | |
| Q2 2020 | -5.3% | -7.6% | -6.7% | |
| Q1 2020 | -1.8% | +4.5% | +11.7% | |
| Q4 2019 | -11.7% | -13.9% | -16.2% | |
| Q3 2019 | +1.1% | +7.1% | +9.2% | |
| Q2 2019 | +6.8% | +9.3% | +15.6% | |
| Q1 2019 | -0.8% | -1.5% | -5.2% | |
| Q4 2018 | +3.4% | +5.1% | -5.2% | |
| Q3 2018 | +0.7% | +1.7% | +8.8% | |
| Q2 2018 | -1.7% | +2.1% | -5.8% | |
| Q1 2018 | -2.2% | -2.7% | -2.7% | |
| Q4 2017 | -0.2% | +0.2% | -3.0% | |
| Q3 2017 | +0.3% | +1.1% | +6.6% | |
| Q2 2017 | -0.4% | -2.7% | -1.1% | |
| Q1 2017 | +0.4% | -0.2% | +3.7% | |
| Q4 2016 | -1.2% | +1.0% | +1.1% | |
| Q3 2016 | +0.8% | +1.1% | +10.4% | |
| Q2 2016 | -1.3% | -2.0% | -2.6% | |
| Q1 2016 | +1.8% | — | — | |
| Q4 2015 | +0.9% | — | — | |
| Q3 2015 | +4.6% | — | — | |
| Q2 2015 | -3.2% | — | — | |
| Q1 2015 | +2.1% | — | — | |
| Q4 2014 | -4.7% | — | — | |
| Q3 2014 | -0.0% | — | — | |
| Q2 2014 | +2.8% | — | — | |
| Q1 2014 | -6.5% | — | — | |
| Q4 2013 | +1.4% | — | — | |
| Q3 2013 | -0.7% | — | — | |
| Q2 2013 | +0.7% | — | — | |
| Q1 2013 | +3.6% | — | — | |
| Q4 2012 | +6.8% | — | — | |
| Q4 2011 | +6.8% | — | — | |
| Q3 2012 | +1.9% | — | — | |
| Q2 2012 | -0.1% | — | — | |
| Q1 2011 | -0.1% | — | — | |
| Q1 2012 | -0.7% | — | — | |
| Q4 2009 | -0.8% | — | — | |
| Q3 2010 | -2.3% | — | — | |
| Q3 2011 | -2.3% | — | — | |
| Q4 2010 | -1.4% | — | — | |
| Q2 2011 | -1.4% | — | — | |
| Q2 2010 | -1.4% | — | — | |
| Q1 2010 | +4.4% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro